OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry

Rhea-AI Summary

OneMedNet (Nasdaq: ONMD) announced the next phase of its commercial launch for a Palantir Foundry–powered Real‑World Data (RWD) platform on February 27, 2026. The company is converting evaluations into multi‑year subscriptions said to represent millions in incremental ARR and scaling an iRWD network spanning 2,130+ healthcare sites.

The platform claims continuous live feeds, 20+ years of historical depth, three years forward coverage, AI‑driven search, faster cohort feasibility, and broader multimodal data to support RWE generation and recurring, high‑margin revenue growth.

Positive

• Multi‑year subscriptions converting now, representing millions in incremental ARR
• Network scale: over 2,130 healthcare sites integrated into iRWD
• Longitudinal depth: 20+ years historical data with 3 years forward coverage
• AI capability: conversational AI search and faster cohort feasibility (weeks to minutes)
• High‑margin recurring revenue model supported by subscription expansion

Negative

• None.

News Market Reaction – ONMD

+44.60% 452.4x vol

37 alerts

+44.60% News Effect

+92.8% Peak in 2 hr 27 min

+$22M Valuation Impact

$71M Market Cap

452.4x Rel. Volume

On the day this news was published, ONMD gained 44.60%, reflecting a significant positive market reaction. Argus tracked a peak move of +92.8% during that session. Our momentum scanner triggered 37 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $22M to the company's valuation, bringing the market cap to $71M at that time. Trading volume was exceptionally heavy at 452.4x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Current price: $0.7054 Price change: 8.86% Volume: 527,080 shares +5 more

8 metrics

Current price $0.7054 Pre-news trading on 2026-02-27

Price change 8.86% Move over prior 24 hours

Volume 527,080 shares Today vs 20-day average 235,389

52-week range $0.30–$4.22 ONMD vs 52-week low/high

iRWD network sites 2,130+ sites Healthcare sites in OneMedNet iRWD network

Historical data span 20+ years Longitudinal depth of live datasets

Forward data horizon 3 years Longitudinal access reliably extending forward

Network demo date November 10, 2025 Live feeds and AI search demonstration

Market Reality Check

Price: $1.02 Vol: Volume 527,080 is 2.24x t...

high vol

$1.02 Last Close

Volume Volume 527,080 is 2.24x the 20-day average of 235,389, signaling elevated interest into this launch update. high

Technical Shares at $0.7054 are trading below the 200-day MA of $1.03 and remain 83.28% under the 52-week high of $4.22.

Peers on Argus

ONMD gained 8.86% while momentum data show mixed peer moves: HCTI appeared in sc...

1 Up 1 Down

ONMD gained 8.86% while momentum data show mixed peer moves: HCTI appeared in scanners moving up 4.79% and VSEE down 5.46%. Sector-wide rotation is not confirmed, pointing to a company-specific reaction.

Historical Context

5 past events · Latest: Feb 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	Strategic partnership	Positive	+8.9%	Partnership with ViuHealth to expand autoimmune iRWD data and subscriptions.
Feb 24	Data partnership	Positive	+2.4%	Risorius EEG/PSG data deal under multi-year subscription licensing model.
Feb 12	Bookings update	Positive	+18.3%	Reported record 2025 bookings of $2.79M, 4.1x 2024, boosting outlook.
Jan 22	Regulatory support	Positive	+12.1%	ONMD data supported FDA 510(k) clearance for AI BrainCT-ICH software.
Jan 16	Large data feed	Positive	+5.9%	Delivered 1.5M-patient RWD feed with 4M encounters under subscription model.

Pattern Detected

Recent ONMD news has consistently produced positive price reactions following commercially oriented and data/AI milestones.

Recent Company History

Over the last few months, ONMD has reported several commercially focused and data-driven milestones. Record 2025 bookings of $2.79M and multiple multi-year data partnerships (Risorius, ViuHealth) supported recurring revenue growth and produced double-digit positive moves (up to 18.29%). Regulatory validation via FDA 510(k)-supported data and large-scale feeds (1.5M patients, 4M encounters) reinforced its AI-ready RWD positioning. Today’s Palantir-powered platform launch phase and subscription expansion fit this trajectory of scaling iRWD™ capabilities and recurring contracts.

Market Pulse Summary

The stock surged +44.6% in the session following this news. A strong positive reaction aligns with O...

Analysis

The stock surged +44.6% in the session following this news. A strong positive reaction aligns with ONMD’s recent pattern, where data-centric and commercial milestones often preceded gains of up to 18.29%. This platform launch phase emphasizes multi-year subscriptions and scaling an iRWD™ network of 2,130+ sites with 20+ years of live data. While shares still trade 83.28% below the $4.22 52-week high and under the $1.03 200-day MA, investors have previously rewarded similar steps toward recurring revenue and regulatory-grade RWD validation.

Key Terms

real-world data (rwd), real-world evidence (rwe), multimodal data, longitudinal data, +4 more

8 terms

real-world data (rwd) medical

"a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced"

Real-world data are health and clinical information collected outside controlled clinical trials — from sources such as electronic health records, insurance claims, patient registries, wearable devices and pharmacy records. Investors care because this evidence shows how treatments or medical products actually perform in everyday use, informing market demand, regulatory decisions, reimbursement and commercial forecasts; think of it as street-level traffic data that complements lab tests and reduces uncertainty about real-market performance.

real-world evidence (rwe) medical

"organizations generating real-world evidence (RWE). This launch drives rapid expansion"

Real-world evidence (RWE) is information about how drugs, devices or medical practices perform based on data collected outside controlled clinical trials, such as electronic health records, insurance claims, patient registries or wearable devices. For investors, RWE matters because it can reveal how a treatment works in everyday use, influence regulatory and reimbursement decisions, and reduce uncertainty about a product’s market potential—think of it as seeing how a product performs in customers’ homes versus a lab demonstration.

multimodal data medical

"iRWD™ network scales—with over 2,130 healthcare sites and expanding multimodal data—subscription"

Multimodal data is information that combines different types of sources—such as numbers, written reports, photos, audio, and sensor readings—into a single view. For investors it matters because blending these types is like looking at a company with both a microscope and a wide-angle lens: it can reveal risks, trends, or opportunities that a single type of data would miss, improving decision-making, forecasting, and due diligence.

longitudinal data medical

"insights across clinical and imaging, longitudinal data; faster cohort building"

Longitudinal data are measurements collected from the same people, companies, products, or locations repeatedly over time, like taking regular snapshots of a plant’s growth rather than a single photo. For investors, this kind of data reveals trends, persistence, and cause-and-effect patterns that a one-time measurement can miss, improving forecasts, risk assessment, and the ability to judge whether changes are temporary or likely to continue.

ai-powered search technical

"near real-time access to comprehensive regulatory-grade multimodal RWD; AI-powered search for nuanced"

A software tool that uses artificial intelligence to read, organize and rank large amounts of documents and data so users can find the most relevant information quickly. For investors it acts like a smart librarian that not only locates needles in haystacks—earnings notes, regulatory filings, news and research—but also highlights patterns and signals that speed due diligence, idea generation and risk checks.

conversational ai-driven search technical

"combining conversational AI-driven search with scalable, prospective data feeds"

Conversational AI-driven search is a search technology that uses artificial intelligence to understand questions phrased in everyday language and return concise, relevant answers or actions instead of a long list of links. For investors, it matters because it can change how customers and employees find information, improving user engagement and efficiency much like replacing a confusing map with a helpful guide, which can boost revenue, lower costs, and influence a company's competitive position.

subscription contracts financial

"launch drives rapid expansion of subscription contracts, including multi-year deals"

A subscription contract is an agreement in which an investor commits to buy a company’s securities—such as shares, bonds, or options—either immediately or over a set schedule and at pre-agreed terms. Investors should care because these contracts provide companies with predictable capital and can change who controls the company or dilute existing ownership; think of it like signing a recurring order that guarantees both payment to the seller and delivery of the product, but here the product is financial ownership.

annual recurring revenue (arr) financial

"predictable growth and millions in incremental annual recurring revenue (ARR). Network"

Annual Recurring Revenue (ARR) is the predictable amount of money a company expects to earn in a year from its ongoing services or subscriptions. It helps businesses understand their steady income stream, much like knowing how much rent they can count on each year, which is important for planning and growth.

AI-generated analysis. Not financial advice.

MINNEAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced the next phase of commercial launch with its RWD Platform powered by Palantir Foundry. Following the successful November 10, 2025, demonstration of live feeds, subscription access, and AI-driven search at major tradeshows, the Company is actively converting customer evaluations into commercial subscriptions. Early results highlight superior performance, speed and analytical depth, reinforcing OneMedNet’s position for life sciences and healthcare organizations generating real-world evidence (RWE).

This launch drives rapid expansion of subscription contracts, including multi-year deals representing millions in incremental recurring revenue, with adoption growing across life sciences, AI Health Innovators.

As the OneMedNet iRWD™ network scales—with over 2,130 healthcare sites and expanding multimodal data—subscription value rises through greater scale, diversity, real-time access, depth, and insight speed.

Customer feedback from evaluations since Fall 2025 confirms the platform’s strengths: unmatched analytical depth across integrated clinical/longitudinal datasets; accelerated cohort feasibility and discovery; streamlined intuitive workflows; and faster onboarding of diverse data partners.

Benefits for Investors
Commercial launch advances OneMedNet’s high-margin recurring revenue model. Evaluation conversions to multi-year subscriptions are happening now, which we believe will drive predictable growth and millions in incremental annual recurring revenue (ARR). Network expansion should boost deal sizes and penetration in life sciences/AI/research, fueling sustained bookings.

Benefits for Customers
Life sciences teams, health systems, and researchers are expected to gain near real-time access to comprehensive regulatory-grade multimodal RWD; AI-powered search for nuanced insights across clinical and imaging, longitudinal data; faster cohort building/feasibility (weeks to minutes); and tools enhancing RWE study design, submissions, and evidence generation—accelerating innovation and reducing trial risks.

Every dataset integrated into the OneMedNet iRWD platform powered by Palantir Foundry is truly live—continuously connected to its source in real time. This industry-unique capability delivers immense power: subscriptions provide assured, ongoing longitudinal access spanning 20+ years of historical depth and reliably extending 3 years forward, fueling richer, more desirable datasets that drive deeper insights, iterative AI/model development, and sustained evidence generation.

“OneMedNet’s platform is redefining how organizations access and operationalize real-world data through the continued expansion of our products and solutions,” said Aaron Green, CEO & President. “Customer feedback has reinforced the platform’s performance, speed, and depth of discovery. We believe this traction validates our strategy of combining conversational AI-driven search with scalable, prospective data feeds, strengthening customer confidence as we expand subscriptions and deliver fast, intuitive value for Real-World evidence generation.”

About OneMedNet Corporation

OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.

Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information.

Learn more at www.onemednet.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements.  These statements include, but are not limited to, statements regarding our products, plans and strategies, and our ability to achieve our operational strategies.

Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

OneMedNet Contacts:

Michael Wong, VP Marketing

Email: michael.wong@onemednet.com

SOURCE: ONEMEDNET CORPORATION

FAQ

What did OneMedNet (ONMD) announce on February 27, 2026 about its commercial launch?

OneMedNet announced the next phase of its commercial launch for an iRWD platform powered by Palantir Foundry. According to the company, it is converting evaluations to multi‑year subscriptions and scaling a network across over 2,130 healthcare sites, aiming to grow recurring ARR.

How much incremental ARR did OneMedNet (ONMD) say the new subscriptions will generate?

The company said conversions are expected to generate millions in incremental ARR. According to the company, early commercial deals are multi‑year subscriptions that should add predictable, high‑margin recurring revenue over time.

What scale of data access does OneMedNet (ONMD) claim its iRWD network provides?

OneMedNet claims an iRWD network spanning 2,130+ healthcare sites with multimodal data access. According to the company, the platform provides continuous live feeds, 20+ years of historical depth and three years of forward coverage.

What capabilities does the Palantir Foundry‑powered RWD platform (ONMD) offer customers?

The platform offers AI‑driven conversational search, integrated clinical and imaging data, and accelerated cohort feasibility. According to the company, these capabilities enable faster onboarding, richer insights, and streamlined RWE study design and submissions.

How does OneMedNet (ONMD) say the platform affects cohort building and feasibility timelines?

OneMedNet states cohort feasibility and discovery can accelerate from weeks to minutes using its platform. According to the company, real‑time connected feeds and AI search materially speed cohort identification and enable rapid feasibility assessments.

What investor benefits did OneMedNet (ONMD) highlight from the commercial launch?

The company emphasized advancement of a high‑margin recurring revenue model and predictable growth from subscription conversions. According to the company, network expansion and multi‑year deals should increase deal sizes and fuel sustained bookings.